Cancer Research and Biotechnology AG

Cancer Research and Biotechnology AG (CRB) is a late preclinical biopharma company, developing treatments for cancer and other degenerative diseases based on its discovery and innovation in Reverse Carcinogenesis. The first drug candidate has patents pending, and early proof of concept is documented. The safety for human use is already well established already during the preclinical stage. We found that cancer can be curable as it is a metabolic disease by its origin. CRB is developing innovations to reverse the cellular processes that lead to mitochondrial dysfunctions - a root cause of genetic errors, tumors and degeneration. Healthy aging is a reality. The first target disease is triple-negative breast cancer (TNBC), a hard-to-treat cancer attacking younger women and mothers.